|  Help  |  About  |  Contact Us

Publication : IKKα inactivation promotes Kras-initiated lung adenocarcinoma development through disrupting major redox regulatory pathways.

First Author  Song NY Year  2018
Journal  Proc Natl Acad Sci U S A Volume  115
Issue  4 Pages  E812-E821
PubMed ID  29311298 Mgi Jnum  J:260592
Mgi Id  MGI:6113759 Doi  10.1073/pnas.1717520115
Citation  Song NY, et al. (2018) IKKalpha inactivation promotes Kras-initiated lung adenocarcinoma development through disrupting major redox regulatory pathways. Proc Natl Acad Sci U S A 115(4):E812-E821
abstractText  Lung adenocarcinoma (ADC) and squamous cell carcinoma (SCC) are two distinct and predominant types of human lung cancer. IkappaB kinase alpha (IKKalpha) has been shown to suppress lung SCC development, but its role in ADC is unknown. We found inactivating mutations and homologous or hemizygous deletions in the CHUK locus, which encodes IKKalpha, in human lung ADCs. The CHUK deletions significantly reduced the survival time of patients with lung ADCs harboring KRAS mutations. In mice, lung-specific Ikkalpha ablation (Ikkalpha(DeltaLu) ) induces spontaneous ADCs and promotes Kras(G12D)-initiated ADC development, accompanied by increased cell proliferation, decreased cell senescence, and reactive oxygen species (ROS) accumulation. IKKalpha deletion up-regulates NOX2 and down-regulates NRF2, leading to ROS accumulation and blockade of cell senescence induction, which together accelerate ADC development. Pharmacologic inhibition of NADPH oxidase or ROS impairs Kras(G12D)-mediated ADC development in Ikkalpha(DeltaLu) mice. Therefore, IKKalpha modulates lung ADC development by controlling redox regulatory pathways. This study demonstrates that IKKalpha functions as a suppressor of lung ADC in human and mice through a unique mechanism that regulates tumor cell-associated ROS metabolism.
Quick Links:
 
Quick Links:
 

Expression

Publication --> Expression annotations

 

Other

8 Bio Entities

Trail: Publication

0 Expression